Study details
Enrolling now
Measuring Dupilumab's Effect on Lung Clearing
Sally E. Wenzel MD
NCT IDNCT04743791ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
30
Study length
about 4 years
Ages
18+
Locations
1 site in PA
What this study is about
This trial is testing if a drug called dupilumab helps improve lung clearing in adults with moderate to severe asthma. Participants will receive either dupilumab or a placebo for 1444 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take Dupilumab
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
dupilumab
Endpoints
Primary: Change in mucociliary clearance (MCC) rate
Secondary: Change in FEV1% predicted
Body systems
Respiratory